Publications by authors named "Brenda Trail"

Claim this Profile
T
The discovery of the benzazepine class of histamine H3 receptor antagonists.
David M Wilson, James Apps, Nicholas Bailey, Mark J Bamford, Isabel J Beresford, Brenda K Trail

Bioorg Med Chem Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.
David M Wilson, James Apps, Nicholas Bailey, Mark J Bamford, Isabel J Beresford, Brenda Trail

Bioorg Med Chem Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.
Giancarlo Trani, Stuart M Baddeley, Michael A Briggs, Tsu T Chuang, Nigel J Deeks, Brenda K Trail

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Andrew D Medhurst, Alan R Atkins, Isabel J Beresford, Kim Brackenborough, Michael A Briggs, Brenda K Trail

J Pharmacol Exp Ther· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
Andrew D Medhurst, Michael A Briggs, Gordon Bruton, Andrew R Calver, Iain Chessell, Brenda K Trail

Biochem Pharmacol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists.
Mahmood Ahmed, Michael A Briggs, Steven M Bromidge, Tania Buck, Lorraine Campbell, Brenda Trail

Bioorg Med Chem Lett· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.
Caroline J Goodacre, Steven M Bromidge, David Clapham, Frank D King, Peter J Lovell, Brenda K Trail

Bioorg Med Chem Lett· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
8
8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
Tom D Heightman, Laramie M Gaster, Sarah L Pardoe, Jean-Pierre Pilleux, Michael S Hadley, Brenda K Trail

Bioorg Med Chem Lett· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postsynaptic 5-HT1B receptors modulate electroshock-induced generalised seizures in rats.
Tania O Stean, Alan R Atkins, Christian A Heidbreder, Leann P Quinn, Brenda K Trail

Br J Pharmacol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LABORAS: Initial pharmacological validation of a system allowing continuous monitoring of laboratory rodent behaviour.
Leann P Quinn, Tania O Stean, Brenda Trail, Mark S Duxon, Sharon C Stratton

J Neurosci Methods· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis